Tokuyama (4043) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
13 Jun, 2025Executive summary
Revenue declined year-over-year due to exclusion of Excel Shannon from consolidation and sluggish semiconductor-related sales, but a full recovery is expected in the second half.
Operating profit increased 45.9% to ¥7,502 million, and net income attributable to owners rose 72.0% to ¥7,402 million, driven by lower manufacturing costs and higher caustic soda exports.
Special gains from investment securities sales, Sun-Tox integration, and business reorganization contributed to higher pre-tax profit.
Progress is in line with expectations, and full-year earnings guidance and dividend forecast remain unchanged.
Financial highlights
Revenue: ¥82.5 billion, down 2.8% (¥2.3 billion) year-over-year.
Operating profit: ¥7.5 billion, up 45.9% (¥2.3 billion) year-over-year.
Net income attributable to parent: ¥7.4 billion, up 72% (¥3.0 billion) year-over-year.
EPS: ¥102.89, up from ¥59.82 year-over-year.
Gross profit increased to ¥26,855 million, with cost of sales down 8.7% year-over-year.
Outlook and guidance
Full-year revenue forecast maintained at ¥352.0 billion (+2.9% year-over-year).
Full-year operating profit forecast unchanged at ¥33.0 billion (+28.7% year-over-year).
Net income forecast at ¥25.0 billion (+40.8% year-over-year), with EPS projected at ¥347.48.
Dividend forecast unchanged at ¥100 per share for the year.
Semiconductor-related product demand expected to recover in the second half.
Latest events from Tokuyama
- Operating profit surged on strong semiconductor sales and acquisitions, despite lower revenue.4043
Q3 202630 Jan 2026 - Operating profit up 37.2% on cost improvements and semiconductor demand; major acquisition completed.4043
Q2 202629 Oct 2025 - Operating profit rose 5.1% despite lower sales, driven by cost improvements and semiconductor demand.4043
Q1 202629 Jul 2025 - Operating and net profit soared on cost cuts and semiconductor demand, with outlook steady.4043
Q2 202513 Jun 2025 - Profits and sales are set to reach record highs, with a major healthcare acquisition ahead.4043
Q4 20256 Jun 2025 - Semiconductor and dental materials strength drove profit growth and revised guidance.4043
Q3 20255 Jun 2025